Posted in General 
July 23rd, 2009

Celgene Corp. (Nasdaq: CELG) shares are up more than 10 percent to $51.97 in premarket volume of more than 60,000 shares shortly after 8 a.m. Eastern. The company reported in-line earnings of 64 cents a share, and revenue that rose 10 percent to $629 million, slightly ahead of consensus. The company reported that its Revlimid net procedure sales increased 22 percent to $397 million, while Vidaza net produce sales rose 54 percent to $92 million. — Mike Tarsala

Comments are closed